Stocks
Tiziana Life Sciences LtdTLSA
NASDAQHealthcareBiotechnology$0.88
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for inflammatory and autoimmune diseases, with a focus on multiple sclerosis and COVID-19. Its lead candidate, foralumab, is an anti-CD3 monoclonal antibody administered nasally, and the company is advancing it through Phase 2 trials. Investors track TLSA for its novel approach to modulating the immune system and its potential in treating neurological conditions.
52W Range: $0.76-$2.10
Congressional Interest in Tiziana Life Sciences Ltd (TLSA)
No congressional trades have been disclosed for Tiziana Life Sciences Ltd (TLSA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TLSA?
No congressional trades found for this stock.